Addressing Unmet Needs In Melanoma

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Addressing Unmet Needs In Melanoma

Playback speed

10 seconds

ASCO 2022 Updates on DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A Phase III Trial - ECOG-ACRIN EA6134

By ASCO 2022 Conference Coverage FEATURING Michael Atkins

215 views

August 19, 2022

Comments 0

ASCO 2022 Long-Term Survival in Advanced Melanoma for Pts Treated Wi…

ASCO 2022 Conference Coverage

P. Rutkowski

132 views

ASCO 2022 on RELATIVITY-047 Trial: Nivolumab + Relatlimab vs. Nivo i…

ASCO 2022 Conference Coverage

P. Rutkowski

1.1K views

ASCO 2022: Real-World Evaluation of the Association Between Baseline…

ASCO 2022 Conference Coverage

Z. Eroglu

130 views

ASCO 2022 on ImmunoCobiVem Study Interim Analysis: The Efficacy & Sa…

ASCO 2022 Conference Coverage

E. Livingstone

124 views

ASCO 2022 Phase II SECOMBIT Study on Optimal Treatment Sequencing in…

ASCO 2022 Conference Coverage

P. Ascierto

110 views

ASCO 2022 on the Role of Metastasectomy in Advanced BRAF+ Melanoma D…

ASCO 2022 Conference Coverage

K. Orlova

300 views

ASCO 2022 Meta-Analysis of Randomized Phase II-III Trials Evaluating…

ASCO 2022 Conference Coverage

P. Francesco Ferrucci

110 views

Lecture Summary - ASCO 2022 Meta-Analysis of Randomized Phase II-III…

ASCO 2022 Conference Coverage

P. Francesco Ferrucci

11 views

ASCO 2022 Melanoma Updates

Total Health

G. Doolittle

263 views

Penn Medicine on the Treatment Updates in Melanoma: Head-Spinning Pr…

Penn Medicine Abramson Cancer Center

L. Schuchter

251 views

ASCO 2022 Nivo + Rela vs. Nivo in Previously Untreated Metastatic/Un…

ASCO 2022 Conference Coverage

E. Lipson

336 views

ASCO 2022 on Anti-PD-1 Antibody: Plus One or Plus Two

ASCO 2022 Conference Coverage

A. Daud

270 views

Lecture Summary - ASCO 2022 on Anti-PD-1 Antibody: Plus One or Plus …

ASCO 2022 Conference Coverage

A. Daud

15 views